Trial Outcomes & Findings for Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia (NCT NCT00611806)

NCT ID: NCT00611806

Last Updated: 2014-08-19

Results Overview

The change from baseline on the Positive and Negative Syndrome Scale (PANSS).The PANNS has three subscales: positive (score range 7-49), negative (score range 7-49), and general psychopathology (score range 16-112). The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7, representing positive symptoms of schizophrenia. The PANSS negative symptom subscale is comprised of 7 items rated on a scale of 1-7 representing the negative symptoms of schizophrenia, and the general psychopathology subscale is comprised of 16 items rated on a scale of 1-7 representing symptoms of general psychopathology in mental illness. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

140 participants

Primary outcome timeframe

Baseline vs. Week 16

Results posted on

2014-08-19

Participant Flow

189 Participants were screened for enrollment, but 49 were excluded. 40 were ineligible, 2 withdrew consent, 1 terminated because of an adverse event, and 6 were terminated because of study visit noncompliance.

Participant milestones

Participant milestones
Measure
Folate With B12
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Overall Study
STARTED
94
46
Overall Study
COMPLETED
78
43
Overall Study
NOT COMPLETED
16
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Folate With B12
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Overall Study
Withdrawal by Subject
8
2
Overall Study
Adverse Event
2
1
Overall Study
Lost to Follow-up
6
0

Baseline Characteristics

Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Folate With B12
n=94 Participants
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
n=46 Participants
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Total
n=140 Participants
Total of all reporting groups
Age, Continuous
45.3 Years
STANDARD_DEVIATION 1.1 • n=99 Participants
45.9 Years
STANDARD_DEVIATION 1.6 • n=107 Participants
45.6 Years
STANDARD_DEVIATION 1.35 • n=206 Participants
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
94 Participants
n=99 Participants
46 Participants
n=107 Participants
140 Participants
n=206 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Sex: Female, Male
Female
28 Participants
n=99 Participants
32 Participants
n=107 Participants
60 Participants
n=206 Participants
Sex: Female, Male
Male
66 Participants
n=99 Participants
14 Participants
n=107 Participants
80 Participants
n=206 Participants
Region of Enrollment
United States
94 participants
n=99 Participants
46 participants
n=107 Participants
140 participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline vs. Week 16

Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135). 120 participants completed the study to the week 16 endpoint; however, 15 participants did not complete the entire 16 weeks, but completed at least one post-baseline study visit where the PANSS assessment was performed.

The change from baseline on the Positive and Negative Syndrome Scale (PANSS).The PANNS has three subscales: positive (score range 7-49), negative (score range 7-49), and general psychopathology (score range 16-112). The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7, representing positive symptoms of schizophrenia. The PANSS negative symptom subscale is comprised of 7 items rated on a scale of 1-7 representing the negative symptoms of schizophrenia, and the general psychopathology subscale is comprised of 16 items rated on a scale of 1-7 representing symptoms of general psychopathology in mental illness. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.

Outcome measures

Outcome measures
Measure
Folate With B12
n=89 Participants
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
n=46 Participants
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Positive and Negative Syndrome Scale (PANSS)
-.21 units on a scale
Interval -0.35 to -0.07
-.22 units on a scale
Interval -0.42 to -0.03

SECONDARY outcome

Timeframe: Measured at Week 16

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline vs. Week 16

Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135). 120 participants completed the study to the week 16 endpoint; however, 15 participants did not complete the entire 16 weeks, but completed at least one post-baseline study visit where the PANSS assessment was performed.

The change from baseline on the positive symptom sub-scale of the Positive and Negative Syndrome Scale (PANSS). Total PANSS positive symptom sub-scale scores range from 7-49. The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. A score of one on each item 1 absent, 2 is minimal, 3 is mild, 4 is moderate, 5 is moderately severe, 6 is severe, and 7 is extreme. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.

Outcome measures

Outcome measures
Measure
Folate With B12
n=89 Participants
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
n=46 Participants
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Positive Sub Scale of the Positive and Negative Syndrome Scale (PANSS)
-.06 units on a scale
Interval -0.12 to -0.01
-.04 units on a scale
Interval -0.11 to 0.03

SECONDARY outcome

Timeframe: Baseline vs. Week 16

Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135). 120 participants completed the study to the week 16 endpoint; however, 15 participants did not complete the entire 16 weeks, but completed at least one post-baseline study visit where the SANS assessment was performed.

The change from baseline on the scale for the assessment of negative symptoms (SANS) total score. Total SANS scores range from 0-100. The SANS is comprised of 5 subscores: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each scale, the higher the score the more prominent the negative symptoms were. The total score was computed by adding all the sub-scale total scores. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total SANS score per week, whereas a positive score represents an increase in total SANS score per week.

Outcome measures

Outcome measures
Measure
Folate With B12
n=89 Participants
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
n=46 Participants
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Scale for Assessment of Negative Symptoms (SANS)
-.19 units on a scale
Interval -0.35 to -0.03
.02 units on a scale
Interval -0.21 to 0.24

SECONDARY outcome

Timeframe: Baseline vs. Week 16

Population: Participants analyzed were those who completed at least 1 post-baseline visit or more (n = 135) and agreed to the DNA blood draw (n = 120).

The change from baseline on the Positive and Negative Syndrome Scale (PANSS) (including FOLH1, MTHRF, MTR, and COMT genotype simultaneously into a linear mixed model).The PANNS has three sub-scales: positive (score range 7-49), negative (score range 7-49), and general psychopathology (score range 16-112). The PANSS negative and positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7 representing the negative and positive symptoms of schizophrenia, respectively, and the general psychopathology sub-scale is comprised of 16 items rated on a scale of 1-7 representing symptoms of general psychopathology in mental illness. The total score was computed by adding all the items on the sub-scale together. Scores reported are change in symptoms per week, relative to baseline. A negative score represents a decrease in total PANSS score per week, whereas a positive score represents an increase in total PANSS score per week.

Outcome measures

Outcome measures
Measure
Folate With B12
n=79 Participants
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
n=41 Participants
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Positive and Negative Syndrome Scale (PANSS) and FOLH1, MTHRF, MTR, and COMT Genotype
-.21 units on a scale
Interval -0.35 to -0.07
-.1 units on a scale
Interval -0.31 to 0.11

SECONDARY outcome

Timeframe: Measured at Week 16

Outcome measures

Outcome data not reported

Adverse Events

Folate With B12

Serious events: 4 serious events
Other events: 21 other events
Deaths: 0 deaths

Placebo

Serious events: 4 serious events
Other events: 16 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Folate With B12
n=94 participants at risk
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
n=46 participants at risk
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Psychiatric disorders
Hospitalization due to worsening psychosis
1.1%
1/94 • Number of events 2
2.2%
1/46 • Number of events 2
Gastrointestinal disorders
Cholelithiasis
1.1%
1/94 • Number of events 1
0.00%
0/46
Nervous system disorders
Body Numbness
0.00%
0/94
2.2%
1/46 • Number of events 1
Psychiatric disorders
Suicidal Tendency
1.1%
1/94 • Number of events 1
0.00%
0/46
Eye disorders
Vision Decreased
0.00%
0/94
2.2%
1/46 • Number of events 1
Nervous system disorders
Brain Tumor
0.00%
0/94
2.2%
1/46 • Number of events 1
Skin and subcutaneous tissue disorders
Irritation of Skin
1.1%
1/94 • Number of events 1
0.00%
0/46

Other adverse events

Other adverse events
Measure
Folate With B12
n=94 participants at risk
Participants will take folic acid plus B12 for 18 weeks. Folic Acid: Folic acid 2mg po daily B12: B12 400 micrograms po daily
Placebo
n=46 participants at risk
Participants will take placebo for 18 weeks. Placebo: 1 capsule po daily
Nervous system disorders
Constipation
2.1%
2/94 • Number of events 2
0.00%
0/46
Cardiac disorders
Tachycardia
1.1%
1/94 • Number of events 1
0.00%
0/46
Endocrine disorders
Hypoglycemia
1.1%
1/94 • Number of events 1
0.00%
0/46
Gastrointestinal disorders
Cholelithiasis
1.1%
1/94 • Number of events 2
0.00%
0/46
Gastrointestinal disorders
Dirrhea
1.1%
1/94 • Number of events 1
0.00%
0/46
Gastrointestinal disorders
Dry Mouth
1.1%
1/94 • Number of events 1
0.00%
0/46
Gastrointestinal disorders
Nausea
0.00%
0/94
2.2%
1/46 • Number of events 1
Gastrointestinal disorders
Vomiting
0.00%
0/94
2.2%
1/46 • Number of events 1
Renal and urinary disorders
Enuresis
1.1%
1/94 • Number of events 1
0.00%
0/46
Nervous system disorders
Numbness
0.00%
0/94
2.2%
1/46 • Number of events 1
Psychiatric disorders
Delusions
0.00%
0/94
2.2%
1/46 • Number of events 2
Nervous system disorders
Dizziness
0.00%
0/94
2.2%
1/46 • Number of events 1
Nervous system disorders
Injury
0.00%
0/94
2.2%
1/46 • Number of events 1
Nervous system disorders
Insomnia
1.1%
1/94 • Number of events 1
0.00%
0/46
Psychiatric disorders
Manic Psychosis
1.1%
1/94 • Number of events 1
0.00%
0/46
Nervous system disorders
Muscle Spasm
1.1%
1/94 • Number of events 1
0.00%
0/46
Psychiatric disorders
Psychosis
3.2%
3/94 • Number of events 3
2.2%
1/46 • Number of events 1
Nervous system disorders
Somnolence
1.1%
1/94 • Number of events 1
2.2%
1/46 • Number of events 1
Psychiatric disorders
Suicidal Tendency
1.1%
1/94 • Number of events 1
0.00%
0/46
General disorders
Back Pain
0.00%
0/94
2.2%
1/46 • Number of events 1
General disorders
Chest Pain
0.00%
0/94
2.2%
1/46 • Number of events 1
General disorders
Malaise
1.1%
1/94 • Number of events 1
0.00%
0/46
Eye disorders
Eye Blood Shot
0.00%
0/94
2.2%
1/46 • Number of events 1
Eye disorders
Vision Decreased
0.00%
0/94
2.2%
1/46 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Asthema
0.00%
0/94
2.2%
1/46 • Number of events 1
Nervous system disorders
Brain Tumor
0.00%
0/94
2.2%
1/46 • Number of events 1
Infections and infestations
Infection
1.1%
1/94 • Number of events 1
0.00%
0/46
General disorders
Laboratory Test Abnormality
1.1%
1/94 • Number of events 1
0.00%
0/46
Skin and subcutaneous tissue disorders
Irritation of Skin
1.1%
1/94 • Number of events 1
0.00%
0/46
Skin and subcutaneous tissue disorders
Rash
1.1%
1/94 • Number of events 1
0.00%
0/46
Skin and subcutaneous tissue disorders
Urticaria
0.00%
0/94
4.3%
2/46 • Number of events 2

Additional Information

Joshua L. Roffman, MD

Massachusetts General Hospital

Phone: 617-724-1920

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place